Intrinsic value of Amyris - AMRS

Previous Close

$3.87

  Intrinsic Value

$128.75

stock screener

  Rating & Target

str. buy

+999%

Previous close

$3.87

 
Intrinsic value

$128.75

 
Up/down potential

+999%

 
Rating

str. buy

We calculate the intrinsic value of AMRS stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  230
  355
  530
  769
  1,086
  1,492
  2,003
  2,630
  3,385
  4,275
  5,309
  6,490
  7,823
  9,308
  10,944
  12,731
  14,665
  16,744
  18,963
  21,320
  23,812
  26,435
  29,189
  32,071
  35,081
  38,221
  41,490
  44,891
  48,428
  52,104
Variable operating expenses, $m
  111
  171
  256
  372
  524
  721
  968
  1,270
  1,635
  2,065
  2,564
  3,135
  3,779
  4,496
  5,286
  6,149
  7,083
  8,087
  9,159
  10,298
  11,501
  12,768
  14,098
  15,490
  16,944
  18,461
  20,040
  21,683
  23,391
  25,166
Fixed operating expenses, $m
  136
  139
  142
  145
  148
  152
  155
  158
  162
  165
  169
  173
  176
  180
  184
  188
  193
  197
  201
  206
  210
  215
  219
  224
  229
  234
  239
  245
  250
  255
Total operating expenses, $m
  247
  310
  398
  517
  672
  873
  1,123
  1,428
  1,797
  2,230
  2,733
  3,308
  3,955
  4,676
  5,470
  6,337
  7,276
  8,284
  9,360
  10,504
  11,711
  12,983
  14,317
  15,714
  17,173
  18,695
  20,279
  21,928
  23,641
  25,421
Operating income, $m
  -17
  44
  132
  253
  413
  620
  881
  1,202
  1,588
  2,045
  2,576
  3,183
  3,868
  4,632
  5,474
  6,394
  7,389
  8,460
  9,603
  10,817
  12,101
  13,452
  14,871
  16,356
  17,908
  19,526
  21,211
  22,964
  24,787
  26,682
EBITDA, $m
  -6
  61
  157
  289
  464
  690
  975
  1,326
  1,748
  2,247
  2,826
  3,489
  4,237
  5,071
  5,991
  6,994
  8,082
  9,250
  10,498
  11,823
  13,224
  14,700
  16,249
  17,870
  19,564
  21,330
  23,169
  25,083
  27,073
  29,142
Interest expense (income), $m
  10
  29
  5
  24
  51
  88
  137
  199
  278
  375
  491
  628
  788
  970
  1,175
  1,404
  1,657
  1,932
  2,230
  2,551
  2,893
  3,256
  3,640
  4,045
  4,469
  4,913
  5,378
  5,861
  6,365
  6,890
  7,435
Earnings before tax, $m
  -46
  40
  108
  202
  325
  483
  681
  923
  1,213
  1,554
  1,947
  2,395
  2,898
  3,456
  4,070
  4,737
  5,457
  6,229
  7,052
  7,924
  8,844
  9,812
  10,827
  11,887
  12,995
  14,148
  15,350
  16,599
  17,898
  19,247
Tax expense, $m
  0
  11
  29
  54
  88
  130
  184
  249
  328
  420
  526
  647
  782
  933
  1,099
  1,279
  1,473
  1,682
  1,904
  2,140
  2,388
  2,649
  2,923
  3,210
  3,509
  3,820
  4,144
  4,482
  4,832
  5,197
Net income, $m
  -46
  29
  79
  147
  237
  353
  497
  674
  886
  1,134
  1,421
  1,748
  2,116
  2,523
  2,971
  3,458
  3,984
  4,548
  5,148
  5,785
  6,456
  7,163
  7,903
  8,678
  9,486
  10,328
  11,205
  12,117
  13,065
  14,051

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  227
  351
  525
  762
  1,075
  1,478
  1,983
  2,604
  3,351
  4,233
  5,256
  6,426
  7,746
  9,216
  10,836
  12,605
  14,520
  16,578
  18,775
  21,109
  23,576
  26,173
  28,900
  31,753
  34,734
  37,842
  41,079
  44,447
  47,949
  51,588
Adjusted assets (=assets-cash), $m
  227
  351
  525
  762
  1,075
  1,478
  1,983
  2,604
  3,351
  4,233
  5,256
  6,426
  7,746
  9,216
  10,836
  12,605
  14,520
  16,578
  18,775
  21,109
  23,576
  26,173
  28,900
  31,753
  34,734
  37,842
  41,079
  44,447
  47,949
  51,588
Revenue / Adjusted assets
  1.013
  1.011
  1.010
  1.009
  1.010
  1.009
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
  1.010
Average production assets, $m
  54
  84
  125
  182
  256
  352
  473
  621
  799
  1,009
  1,253
  1,532
  1,846
  2,197
  2,583
  3,005
  3,461
  3,951
  4,475
  5,032
  5,620
  6,239
  6,889
  7,569
  8,279
  9,020
  9,792
  10,594
  11,429
  12,297
Working capital, $m
  -9
  -14
  -21
  -31
  -43
  -60
  -80
  -105
  -135
  -171
  -212
  -260
  -313
  -372
  -438
  -509
  -587
  -670
  -759
  -853
  -952
  -1,057
  -1,168
  -1,283
  -1,403
  -1,529
  -1,660
  -1,796
  -1,937
  -2,084
Total debt, $m
  28
  139
  296
  509
  790
  1,153
  1,608
  2,167
  2,839
  3,633
  4,554
  5,607
  6,794
  8,117
  9,576
  11,168
  12,891
  14,743
  16,721
  18,821
  21,041
  23,379
  25,833
  28,401
  31,084
  33,881
  36,794
  39,825
  42,977
  46,253
Total liabilities, $m
  205
  316
  473
  686
  967
  1,330
  1,785
  2,344
  3,016
  3,809
  4,731
  5,784
  6,971
  8,294
  9,753
  11,345
  13,068
  14,920
  16,898
  18,998
  21,218
  23,556
  26,010
  28,578
  31,261
  34,058
  36,971
  40,002
  43,154
  46,429
Total equity, $m
  23
  35
  53
  76
  107
  148
  198
  260
  335
  423
  526
  643
  775
  922
  1,084
  1,261
  1,452
  1,658
  1,878
  2,111
  2,358
  2,617
  2,890
  3,175
  3,473
  3,784
  4,108
  4,445
  4,795
  5,159
Total liabilities and equity, $m
  228
  351
  526
  762
  1,074
  1,478
  1,983
  2,604
  3,351
  4,232
  5,257
  6,427
  7,746
  9,216
  10,837
  12,606
  14,520
  16,578
  18,776
  21,109
  23,576
  26,173
  28,900
  31,753
  34,734
  37,842
  41,079
  44,447
  47,949
  51,588
Debt-to-equity ratio
  1.220
  3.960
  5.630
  6.680
  7.350
  7.800
  8.110
  8.320
  8.470
  8.580
  8.660
  8.720
  8.770
  8.810
  8.840
  8.860
  8.880
  8.890
  8.910
  8.920
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -46
  29
  79
  147
  237
  353
  497
  674
  886
  1,134
  1,421
  1,748
  2,116
  2,523
  2,971
  3,458
  3,984
  4,548
  5,148
  5,785
  6,456
  7,163
  7,903
  8,678
  9,486
  10,328
  11,205
  12,117
  13,065
  14,051
Depreciation, amort., depletion, $m
  11
  17
  25
  36
  51
  70
  95
  124
  160
  202
  251
  306
  369
  439
  517
  601
  692
  790
  895
  1,006
  1,124
  1,248
  1,378
  1,514
  1,656
  1,804
  1,958
  2,119
  2,286
  2,459
Funds from operations, $m
  -35
  46
  104
  183
  288
  423
  592
  798
  1,045
  1,336
  1,672
  2,055
  2,485
  2,963
  3,487
  4,059
  4,676
  5,338
  6,043
  6,791
  7,580
  8,411
  9,281
  10,192
  11,142
  12,132
  13,163
  14,236
  15,351
  16,510
Change in working capital, $m
  -3
  -5
  -7
  -10
  -13
  -16
  -20
  -25
  -30
  -36
  -41
  -47
  -53
  -59
  -65
  -71
  -77
  -83
  -89
  -94
  -100
  -105
  -110
  -115
  -120
  -126
  -131
  -136
  -141
  -147
Cash from operations, $m
  -32
  51
  111
  193
  301
  440
  612
  823
  1,076
  1,372
  1,713
  2,102
  2,538
  3,022
  3,553
  4,130
  4,753
  5,421
  6,132
  6,885
  7,680
  8,516
  9,391
  10,307
  11,262
  12,258
  13,294
  14,372
  15,493
  16,657
Maintenance CAPEX, $m
  -7
  -11
  -17
  -25
  -36
  -51
  -70
  -95
  -124
  -160
  -202
  -251
  -306
  -369
  -439
  -517
  -601
  -692
  -790
  -895
  -1,006
  -1,124
  -1,248
  -1,378
  -1,514
  -1,656
  -1,804
  -1,958
  -2,119
  -2,286
New CAPEX, $m
  -20
  -30
  -41
  -56
  -75
  -96
  -121
  -148
  -178
  -210
  -244
  -279
  -315
  -350
  -386
  -422
  -456
  -491
  -524
  -556
  -588
  -619
  -650
  -680
  -710
  -741
  -772
  -803
  -835
  -868
Cash from investing activities, $m
  -27
  -41
  -58
  -81
  -111
  -147
  -191
  -243
  -302
  -370
  -446
  -530
  -621
  -719
  -825
  -939
  -1,057
  -1,183
  -1,314
  -1,451
  -1,594
  -1,743
  -1,898
  -2,058
  -2,224
  -2,397
  -2,576
  -2,761
  -2,954
  -3,154
Free cash flow, $m
  -59
  10
  53
  112
  190
  292
  421
  581
  773
  1,002
  1,268
  1,573
  1,917
  2,302
  2,727
  3,192
  3,696
  4,238
  4,818
  5,434
  6,086
  6,772
  7,494
  8,249
  9,038
  9,861
  10,719
  11,611
  12,539
  13,504
Issuance/(repayment) of debt, $m
  -138
  111
  157
  213
  282
  363
  455
  559
  672
  793
  921
  1,053
  1,188
  1,323
  1,458
  1,592
  1,723
  1,852
  1,978
  2,100
  2,220
  2,338
  2,454
  2,568
  2,683
  2,797
  2,913
  3,031
  3,152
  3,276
Issuance/(repurchase) of shares, $m
  269
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  131
  111
  157
  213
  282
  363
  455
  559
  672
  793
  921
  1,053
  1,188
  1,323
  1,458
  1,592
  1,723
  1,852
  1,978
  2,100
  2,220
  2,338
  2,454
  2,568
  2,683
  2,797
  2,913
  3,031
  3,152
  3,276
Total cash flow (excl. dividends), $m
  73
  122
  209
  325
  472
  655
  877
  1,140
  1,446
  1,795
  2,189
  2,626
  3,105
  3,625
  4,186
  4,784
  5,419
  6,090
  6,796
  7,534
  8,306
  9,110
  9,947
  10,817
  11,721
  12,659
  13,632
  14,642
  15,691
  16,779
Retained Cash Flow (-), $m
  -269
  -12
  -17
  -24
  -31
  -40
  -51
  -62
  -75
  -88
  -102
  -117
  -132
  -147
  -162
  -177
  -191
  -206
  -220
  -233
  -247
  -260
  -273
  -285
  -298
  -311
  -324
  -337
  -350
  -364
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -196
  109
  192
  301
  441
  614
  826
  1,078
  1,371
  1,707
  2,086
  2,509
  2,973
  3,478
  4,024
  4,607
  5,228
  5,885
  6,576
  7,301
  8,059
  8,851
  9,675
  10,532
  11,423
  12,348
  13,308
  14,305
  15,340
  16,415
Discount rate, %
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
  -186
  98
  160
  234
  317
  406
  498
  587
  670
  742
  799
  837
  855
  853
  831
  791
  736
  669
  595
  517
  439
  365
  295
  233
  180
  135
  99
  70
  49
  33
Current shareholders' claim on cash, %
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0
  50.0

Amyris, Inc. is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels. The Company focuses on a renewable hydrocarbon molecule called farnesene (Biofene). The Company is expanding its range of products across various categories divided into consumer and industrial applications. For consumer applications, the Company is developing and selling personal care products (which include ingredients for cosmetics and F&F), healthcare products and formulated end user products, such as Biossance brand skincare products and Muck Daddy brand hand cleaner product.

FINANCIAL RATIOS  of  Amyris (AMRS)

Valuation Ratios
P/E Ratio -0.7
Price to Sales 1.1
Price to Book -0.4
Price to Tangible Book
Price to Cash Flow -0.9
Price to Free Cash Flow -0.9
Growth Rates
Sales Growth Rate 97.1%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -66.7%
Cap. Spend. - 3 Yr. Gr. Rate -34%
Financial Strength
Quick Ratio 1
Current Ratio 0.1
LT Debt to Equity -91.3%
Total Debt to Equity -105.4%
Interest Coverage -9
Management Effectiveness
Return On Assets -73.7%
Ret/ On Assets - 3 Yr. Avg. -66.6%
Return On Total Capital -3880%
Ret/ On T. Cap. - 3 Yr. Avg. -1432%
Return On Equity 56.7%
Return On Equity - 3 Yr. Avg. 69.9%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 16.4%
Gross Margin - 3 Yr. Avg. 10.3%
EBITDA Margin -113.4%
EBITDA Margin - 3 Yr. Avg. -203.4%
Operating Margin -149.3%
Oper. Margin - 3 Yr. Avg. -282.9%
Pre-Tax Margin -144.8%
Pre-Tax Margin - 3 Yr. Avg. -252.4%
Net Profit Margin -144.8%
Net Profit Margin - 3 Yr. Avg. -260.4%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 5.4%
Payout Ratio 0%

AMRS stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AMRS stock intrinsic value calculation we used $143.445 million for the last fiscal year's total revenue generated by Amyris. The default revenue input number comes from 0001 income statement of Amyris. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AMRS stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for AMRS is calculated based on our internal credit rating of Amyris, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Amyris.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AMRS stock the variable cost ratio is equal to 48.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $133 million in the base year in the intrinsic value calculation for AMRS stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 17.3% for Amyris.

Corporate tax rate of 27% is the nominal tax rate for Amyris. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AMRS stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AMRS are equal to 23.6%.

Life of production assets of 3 years is the average useful life of capital assets used in Amyris operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AMRS is equal to -4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-200.644 million for Amyris - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 50.338 million for Amyris is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Amyris at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
TOT Total ADR 57.13 222.16  str.buy
GEVO Gevo 3.08 4.49  hold
ALB Albemarle 102.70 107.07  hold
XOM Exxon Mobil 78.19 139.68  str.buy
VLO Valero Energy 83.27 35.62  str.sell
HFC HollyFrontier 63.09 633.31  str.buy
MPC Marathon Petro 65.36 475.51  str.buy

COMPANY NEWS

▶ Here's Why Amyris Can't Stop Sliding This Week   [Nov-16-18 12:25PM  Motley Fool]
▶ Here's Why Amyris Is Getting Obliterated Today   [Nov-14-18 11:17AM  Motley Fool]
▶ Amyris Reports Third Quarter 2018 Financial Results   [Nov-13-18 04:01PM  GlobeNewswire]
▶ Amyris Q3 Earnings Outlook   [08:17AM  Benzinga]
▶ Amyris Inc (NASDAQ:AMRS): Is Breakeven Near?   [Nov-08-18 02:51PM  Simply Wall St.]
▶ Better Synthetic Biology Stock: Amyris vs. Codexis   [Oct-06-18 08:35AM  Motley Fool]
▶ Amyris Provides Update on Leland, NC Production Facility   [Sep-17-18 08:30AM  GlobeNewswire]
▶ Amyris Announces Successful Closing of Secondary Offering   [Aug-21-18 04:30PM  GlobeNewswire]
▶ Amyris, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ Amyris Set to Join Russell Microcap® Index   [Jun-11-18 08:30AM  GlobeNewswire]
▶ Amyris, Inc. to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ Amyris to Participate in Upcoming Investor Conferences   [May-10-18 08:30AM  GlobeNewswire]
▶ Who Really Owns Amyris Inc (NASDAQ:AMRS)?   [Apr-17-18 11:33AM  Simply Wall St.]
▶ Amyris, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ Amyris Announces Over $25 Million in Grants   [Jan-17-18 08:30AM  GlobeNewswire]
▶ ETFs with exposure to Amyris, Inc. : December 11, 2017   [Dec-11-17 01:26PM  Capital Cube]
▶ ETFs with exposure to Amyris, Inc. : November 30, 2017   [Nov-30-17 01:18PM  Capital Cube]
▶ Amyris reports 3Q loss   [Nov-16-17 05:12AM  Associated Press]
▶ Amyris, Inc. to Host Earnings Call   [11:00AM  ACCESSWIRE]
▶ Should You Worry About Amyris Incs (AMRS) CEO Pay?   [Nov-08-17 12:19PM  Simply Wall St.]
▶ ETFs with exposure to Amyris, Inc. : October 27, 2017   [Oct-27-17 10:43AM  Capital Cube]
▶ ETFs with exposure to Amyris, Inc. : October 12, 2017   [Oct-12-17 10:17AM  Capital Cube]
▶ How Does Amyris Inc (AMRS) Affect Your Portfolio Returns?   [Sep-30-17 07:47PM  Simply Wall St.]
▶ ETFs with exposure to Amyris, Inc. : September 28, 2017   [Sep-28-17 10:09AM  Capital Cube]
▶ ETFs with exposure to Amyris, Inc. : September 13, 2017   [Sep-13-17 05:17PM  Capital Cube]
▶ ETFs with exposure to Amyris, Inc. : August 31, 2017   [Aug-31-17 05:13PM  Capital Cube]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.